Uvangoletin  ||| S:0 E:12 ||| NNP
induces  ||| S:12 E:20 ||| VBZ
mitochondria-mediated  ||| S:20 E:42 ||| JJ
apoptosis  ||| S:42 E:52 ||| NN
in  ||| S:52 E:55 ||| IN
HL-60  ||| S:55 E:61 ||| CD
cells  ||| S:61 E:67 ||| NNS
in  ||| S:67 E:70 ||| IN
vitro  ||| S:70 E:76 ||| NN
and  ||| S:76 E:80 ||| CC
in  ||| S:80 E:83 ||| IN
vivo  ||| S:83 E:88 ||| NN
without  ||| S:88 E:96 ||| IN
adverse  ||| S:96 E:104 ||| JJ
reactions  ||| S:104 E:114 ||| NNS
of  ||| S:114 E:117 ||| IN
myelosuppression ||| S:117 E:133 ||| NN
,  ||| S:133 E:135 ||| ,
leucopenia  ||| S:135 E:146 ||| NN
and  ||| S:146 E:150 ||| CC
gastrointestinal  ||| S:150 E:167 ||| JJ
tract  ||| S:167 E:173 ||| NN
disturbances  ||| S:173 E:186 ||| NNS
This  ||| S:186 E:191 ||| DT
study  ||| S:191 E:197 ||| NN
investigated  ||| S:197 E:210 ||| VBD
the  ||| S:210 E:214 ||| DT
cytotoxic  ||| S:214 E:224 ||| JJ
effect  ||| S:224 E:231 ||| NN
of  ||| S:231 E:234 ||| IN
uvangoletin  ||| S:234 E:246 ||| NN
on  ||| S:246 E:249 ||| IN
HL-60  ||| S:249 E:255 ||| CD
cells ||| S:255 E:260 ||| NNS
,  ||| S:260 E:262 ||| ,
and  ||| S:262 E:266 ||| CC
the  ||| S:266 E:270 ||| DT
effects  ||| S:270 E:278 ||| NNS
of  ||| S:278 E:281 ||| IN
uvangoletin  ||| S:281 E:293 ||| NN
on  ||| S:293 E:296 ||| IN
myelosuppression ||| S:296 E:312 ||| NN
,  ||| S:312 E:314 ||| ,
leucopenia ||| S:314 E:324 ||| NN
,  ||| S:324 E:326 ||| ,
gastrointestinal  ||| S:326 E:343 ||| JJ
tract  ||| S:343 E:349 ||| NN
disturbances  ||| S:349 E:362 ||| NNS
and  ||| S:362 E:366 ||| CC
the  ||| S:366 E:370 ||| DT
possible  ||| S:370 E:379 ||| JJ
cytotoxic  ||| S:379 E:389 ||| JJ
mechanisms  ||| S:389 E:400 ||| NNS
by  ||| S:400 E:403 ||| IN
using  ||| S:403 E:409 ||| VBG
CCK-8 ||| S:409 E:414 ||| NNP
,  ||| S:414 E:416 ||| ,
flow  ||| S:416 E:421 ||| NN
cytometry ||| S:421 E:430 ||| NN
,  ||| S:430 E:432 ||| ,
western  ||| S:432 E:440 ||| JJ
blot ||| S:440 E:444 ||| NN
,  ||| S:444 E:446 ||| ,
xenograft ||| S:446 E:455 ||| NN
,  ||| S:455 E:457 ||| ,
cyclophosphamide-induced  ||| S:457 E:482 ||| JJ
leucopenia ||| S:482 E:492 ||| NN
,  ||| S:492 E:494 ||| ,
copper  ||| S:494 E:501 ||| NN
sulfate-induced  ||| S:501 E:517 ||| JJ
emesis  ||| S:517 E:524 ||| NN
and  ||| S:524 E:528 ||| CC
ethanol-induced  ||| S:528 E:544 ||| JJ
gastric  ||| S:544 E:552 ||| FW
mucosal  ||| S:552 E:560 ||| FW
lesions  ||| S:560 E:568 ||| FW
assays ||| S:568 E:574 ||| FW
.  ||| S:574 E:576 ||| .
The  ||| S:576 E:580 ||| DT
results  ||| S:580 E:588 ||| NNS
of  ||| S:588 E:591 ||| IN
CCK-8 ||| S:591 E:596 ||| NNP
,  ||| S:596 E:598 ||| ,
flow  ||| S:598 E:603 ||| NN
cytometry  ||| S:603 E:613 ||| NNS
and  ||| S:613 E:617 ||| CC
western  ||| S:617 E:625 ||| JJ
blot  ||| S:625 E:630 ||| NNS
assays  ||| S:630 E:637 ||| VBP
indicated  ||| S:637 E:647 ||| VBN
that  ||| S:647 E:652 ||| IN
uvangoletin  ||| S:652 E:664 ||| NN
showed  ||| S:664 E:671 ||| VBD
the  ||| S:671 E:675 ||| DT
cytotoxic  ||| S:675 E:685 ||| JJ
effect  ||| S:685 E:692 ||| NN
on  ||| S:692 E:695 ||| IN
HL-60  ||| S:695 E:701 ||| CD
cells  ||| S:701 E:707 ||| NNS
and  ||| S:707 E:711 ||| CC
induced  ||| S:711 E:719 ||| VBN
the  ||| S:719 E:723 ||| DT
apoptosis  ||| S:723 E:733 ||| NN
of  ||| S:733 E:736 ||| IN
HL-60  ||| S:736 E:742 ||| CD
cells  ||| S:742 E:748 ||| NNS
by  ||| S:748 E:751 ||| IN
downregulating  ||| S:751 E:766 ||| VBG
the  ||| S:766 E:770 ||| DT
expression  ||| S:770 E:781 ||| NN
levels  ||| S:781 E:788 ||| NNS
of  ||| S:788 E:791 ||| IN
anti-apoptotic  ||| S:791 E:806 ||| JJ
proteins  ||| S:806 E:815 ||| NNS
( ||| S:815 E:816 ||| -LRB-
Survivin ||| S:816 E:824 ||| NNP
,  ||| S:824 E:826 ||| ,
Bcl-xl  ||| S:826 E:833 ||| JJ
and  ||| S:833 E:837 ||| CC
Bcl-2 ||| S:837 E:842 ||| CD
) ||| S:842 E:843 ||| -RRB-
,  ||| S:843 E:845 ||| ,
upregulating  ||| S:845 E:858 ||| VBG
the  ||| S:858 E:862 ||| DT
expression  ||| S:862 E:873 ||| NN
levels  ||| S:873 E:880 ||| NNS
of  ||| S:880 E:883 ||| IN
pro-apoptotic  ||| S:883 E:897 ||| JJ
proteins  ||| S:897 E:906 ||| NNS
( ||| S:906 E:907 ||| -LRB-
Smac ||| S:907 E:911 ||| NNP
,  ||| S:911 E:913 ||| ,
Bax ||| S:913 E:916 ||| NNP
,  ||| S:916 E:918 ||| ,
Bad ||| S:918 E:921 ||| NNP
,  ||| S:921 E:923 ||| ,
c-caspase-3  ||| S:923 E:935 ||| NNP
and  ||| S:935 E:939 ||| CC
c-caspase-9 ||| S:939 E:950 ||| CD
) ||| S:950 E:951 ||| -RRB-
,  ||| S:951 E:953 ||| ,
and  ||| S:953 E:957 ||| CC
promoting  ||| S:957 E:967 ||| VBG
the  ||| S:967 E:971 ||| DT
release  ||| S:971 E:979 ||| NN
of  ||| S:979 E:982 ||| IN
cytochrome c  ||| S:982 E:995 ||| CD
from  ||| S:995 E:1000 ||| IN
mitochondria  ||| S:1000 E:1013 ||| VBG
to  ||| S:1013 E:1016 ||| TO
cytoplasm ||| S:1016 E:1025 ||| VB
.  ||| S:1025 E:1027 ||| .
Further ||| S:1027 E:1034 ||| RB
,  ||| S:1034 E:1036 ||| ,
the  ||| S:1036 E:1040 ||| DT
results  ||| S:1040 E:1048 ||| NNS
of  ||| S:1048 E:1051 ||| IN
xenograft  ||| S:1051 E:1061 ||| JJ
assay  ||| S:1061 E:1067 ||| NN
suggested  ||| S:1067 E:1077 ||| VBD
that  ||| S:1077 E:1082 ||| DT
uvangoletin  ||| S:1082 E:1094 ||| NN
inhibited  ||| S:1094 E:1104 ||| VBD
the  ||| S:1104 E:1108 ||| DT
HL-60-induced  ||| S:1108 E:1122 ||| JJ
tumor  ||| S:1122 E:1128 ||| NN
growth  ||| S:1128 E:1135 ||| NN
without  ||| S:1135 E:1143 ||| IN
adverse  ||| S:1143 E:1151 ||| JJ
effect  ||| S:1151 E:1158 ||| NN
on  ||| S:1158 E:1161 ||| IN
body  ||| S:1161 E:1166 ||| NN
weight  ||| S:1166 E:1173 ||| NN
of  ||| S:1173 E:1176 ||| IN
nude  ||| S:1176 E:1181 ||| JJ
mice  ||| S:1181 E:1186 ||| NNS
in vivo  ||| S:1186 E:1194 ||| VBP
by  ||| S:1194 E:1197 ||| IN
regulating  ||| S:1197 E:1208 ||| VBG
the  ||| S:1208 E:1212 ||| DT
expression  ||| S:1212 E:1223 ||| NN
levels  ||| S:1223 E:1230 ||| NNS
of  ||| S:1230 E:1233 ||| IN
above  ||| S:1233 E:1239 ||| IN
apoptotic  ||| S:1239 E:1249 ||| JJ
proteins ||| S:1249 E:1257 ||| NNS
.  ||| S:1257 E:1259 ||| .
The  ||| S:1259 E:1263 ||| DT
results  ||| S:1263 E:1271 ||| NNS
indicated  ||| S:1271 E:1281 ||| VBD
that  ||| S:1281 E:1286 ||| IN
the  ||| S:1286 E:1290 ||| DT
reductions  ||| S:1290 E:1301 ||| NNS
of  ||| S:1301 E:1304 ||| IN
WBCs  ||| S:1304 E:1309 ||| JJ
count  ||| S:1309 E:1315 ||| NN
and  ||| S:1315 E:1319 ||| CC
thighbone  ||| S:1319 E:1329 ||| JJ
marrow  ||| S:1329 E:1336 ||| JJ
granulocytes  ||| S:1336 E:1349 ||| JJ
percentage  ||| S:1349 E:1360 ||| NN
in  ||| S:1360 E:1363 ||| IN
cyclophosphamide-induced  ||| S:1363 E:1388 ||| JJ
leucopenia  ||| S:1388 E:1399 ||| JJ
assay ||| S:1399 E:1404 ||| NN
,  ||| S:1404 E:1406 ||| ,
the  ||| S:1406 E:1410 ||| DT
incubation  ||| S:1410 E:1421 ||| JJ
period  ||| S:1421 E:1428 ||| NN
and  ||| S:1428 E:1432 ||| CC
number  ||| S:1432 E:1439 ||| NN
of  ||| S:1439 E:1442 ||| IN
emesis  ||| S:1442 E:1449 ||| NN
in  ||| S:1449 E:1452 ||| IN
copper  ||| S:1452 E:1459 ||| NN
sulfate-induced  ||| S:1459 E:1475 ||| JJ
emesis  ||| S:1475 E:1482 ||| JJ
assay  ||| S:1482 E:1488 ||| NN
and  ||| S:1488 E:1492 ||| CC
the  ||| S:1492 E:1496 ||| DT
gastric  ||| S:1496 E:1504 ||| FW
mucosal  ||| S:1504 E:1512 ||| FW
lesions  ||| S:1512 E:1520 ||| FW
in  ||| S:1520 E:1523 ||| FW
ethanol-induced  ||| S:1523 E:1539 ||| FW
gastric  ||| S:1539 E:1547 ||| FW
mucosal  ||| S:1547 E:1555 ||| FW
lesions  ||| S:1555 E:1563 ||| FW
assay  ||| S:1563 E:1569 ||| NN
were  ||| S:1569 E:1574 ||| VBD
not  ||| S:1574 E:1578 ||| RB
exacerbated  ||| S:1578 E:1590 ||| VBN
or  ||| S:1590 E:1593 ||| CC
reversed  ||| S:1593 E:1602 ||| VBN
by  ||| S:1602 E:1605 ||| IN
uvangoletin ||| S:1605 E:1616 ||| NN
.  ||| S:1616 E:1618 ||| .
In  ||| S:1618 E:1621 ||| IN
conclusion ||| S:1621 E:1631 ||| NN
,  ||| S:1631 E:1633 ||| ,
the  ||| S:1633 E:1637 ||| DT
research  ||| S:1637 E:1646 ||| NN
preliminarily  ||| S:1646 E:1660 ||| VBZ
indicated  ||| S:1660 E:1670 ||| VBN
that  ||| S:1670 E:1675 ||| IN
uvangoletin  ||| S:1675 E:1687 ||| JJ
induced  ||| S:1687 E:1695 ||| JJ
apoptosis  ||| S:1695 E:1705 ||| NN
of  ||| S:1705 E:1708 ||| IN
HL-60  ||| S:1708 E:1714 ||| CD
cells  ||| S:1714 E:1720 ||| NNS
in vitro  ||| S:1720 E:1729 ||| NNP
and  ||| S:1729 E:1733 ||| CC
in vivo  ||| S:1733 E:1741 ||| CD
without  ||| S:1741 E:1749 ||| IN
adverse  ||| S:1749 E:1757 ||| JJ
reactions  ||| S:1757 E:1767 ||| NNS
of  ||| S:1767 E:1770 ||| IN
myelosuppression ||| S:1770 E:1786 ||| NN
,  ||| S:1786 E:1788 ||| ,
leucopenia  ||| S:1788 E:1799 ||| NN
and  ||| S:1799 E:1803 ||| CC
gastrointestinal  ||| S:1803 E:1820 ||| JJ
tract  ||| S:1820 E:1826 ||| NN
disturbances ||| S:1826 E:1838 ||| NNS
,  ||| S:1838 E:1840 ||| ,
and  ||| S:1840 E:1844 ||| CC
the  ||| S:1844 E:1848 ||| DT
pro-apoptotic  ||| S:1848 E:1862 ||| JJ
mechanisms  ||| S:1862 E:1873 ||| NNS
may  ||| S:1873 E:1877 ||| MD
be  ||| S:1877 E:1880 ||| VB
related  ||| S:1880 E:1888 ||| VBN
to  ||| S:1888 E:1891 ||| TO
mitochondria-mediated  ||| S:1891 E:1913 ||| JJ
apoptotic  ||| S:1913 E:1923 ||| JJ
pathway ||| S:1923 E:1930 ||| NN
.  ||| S:1930 E:1932 ||| .
